GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Vistagen Therapeutics
Vistagen Therapeutics is a biotech company developing drugs to treat anxiety disorders and depression. Its stock price is highly volatile and depends on the results of clinical trials of its nasal sprays.
Share prices of companies in the market segment - Neuro
Vistagen Therapeutics develops new medications for the treatment of anxiety disorders and depression, including fast-acting nasal sprays. We classify it in the Neuroscience sector. The chart below shows the overall growth of this important mental health area.
Broad Market Index - GURU.Markets
Vistagen Therapeutics is a biotech company developing innovative nasal sprays for the rapid treatment of anxiety disorders. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Vistagen shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VTGN - Daily change in the company's share price Vistagen Therapeutics
Vistagen Therapeutics' daily stock price fluctuations reflect the extreme volatility inherent in biotech companies operating in the mental health field. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment element.
Daily change in the price of a set of shares in a market segment - Neuro
Vistagen Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies operating in the mental health field. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment element.
Daily change in the price of a broad market stock, index - GURU.Markets
Vistagen Therapeutics develops innovative drugs for the treatment of anxiety disorders and depression. The company's shares are highly volatile and driven by news of clinical trials. This dynamic, based on hopes in the mental health field, contributes to the overall market "noise."
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Vistagen Therapeutics
For Vistagen Therapeutics, the year-over-year trend is a story about developing a new class of drugs for anxiety and depression. Its 12-month market cap depends entirely on the results of clinical trials of its nasal sprays. Success could offer patients a fast-acting, non-addictive alternative to existing treatments.
Annual dynamics of market capitalization of the market segment - Neuro
Vistagen Therapeutics, Inc. is a late-stage biotech developing drugs for the treatment of anxiety disorders and depression. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vistagen is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its anxiety disorder drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Vistagen Therapeutics
Vistagen Therapeutics develops drugs to treat anxiety disorders and depression. Its monthly performance is entirely dependent on the results of clinical trials of its nasal sprays. These trials are binary events, causing sharp fluctuations in its price.
Monthly dynamics of market capitalization of the market segment - Neuro
Vistagen Therapeutics, Inc. is a biopharmaceutical company developing new drugs for the treatment of anxiety disorders and depression. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its innovative nasal sprays, designed to rapidly relieve anxiety symptoms, in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vistagen is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Its shares move not with the market, but on research news. The chart demonstrates extreme volatility and a complete dependence of monthly performance on research successes or failures in trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Vistagen Therapeutics
Vistagen Therapeutics, a biopharmaceutical company developing drugs to treat anxiety and depression, exhibits high volatility. Weekly stock performance hinges on news about clinical trials, where any development could dramatically alter the company's prospects in this vast niche.
Weekly dynamics of market capitalization of the market segment - Neuro
Vistagen Therapeutics develops drugs to treat anxiety and depression. Mental health stocks can react strongly to trial data. The chart will show whether Vistagen's price movements are isolated or reflective of overall sentiment in the CNS drug development sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vistagen Therapeutics develops anti-anxiety drugs. Its shares follow the rhythm of development news. The chart will show how independent VTGN's performance is from general market fluctuations, driven by its unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
VTGN - Market capitalization of the company Vistagen Therapeutics
Vistagen's stock chart is a financial map of the battle against anxiety and depression. Its market cap reflects the hopes for its innovative nasal sprays designed to quickly relieve symptoms. Its volatility reflects the results of clinical trials and the enormous need for new, fast-acting mental health medications.
VTGN - Share of the company's market capitalization Vistagen Therapeutics within the market segment - Neuro
Vistagen Therapeutics' stake in the neuroscience sector is a bet on a new approach to treating anxiety disorders. The company is developing fast-acting nasal sprays. Its market share reflects the potential of its drugs to change the treatment paradigm for conditions affecting millions of people.
Market capitalization of the market segment - Neuro
Vistagen Therapeutics is developing nasal sprays for the rapid treatment of anxiety disorders. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect the urgent need for new, non-addictive mental health medications.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vistagen Therapeutics develops innovative nasal sprays for the rapid relief of anxiety and depression. Its market cap is a bet on a new approach to treating mental disorders. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
VTGN - Book value capitalization of the company Vistagen Therapeutics
Vistagen Therapeutics' book value represents its R&D capital. The chart below shows its financial resources for developing anxiety medications. This level is an indicator of its ability to fund clinical trials of its innovative nasal sprays.
VTGN - Share of the company's book capitalization Vistagen Therapeutics within the market segment - Neuro
Vistagen Therapeutics is developing nasal sprays for the treatment of anxiety disorders. Its value lies in its scientific platform. The share of tangible assets will be minimal, typical for an R&D company whose primary capital is intellectual rather than industrial.
Market segment balance sheet capitalization - Neuro
Vistagen Therapeutics is a biotech company whose value is created in laboratories developing drugs for anxiety disorders. It's a "lightweight" model based on science. The chart below illustrates how much the pharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Vistagen's balance sheet represents capital invested in the development of innovative nasal sprays for the rapid treatment of anxiety disorders and depression. The company's assets represent the hope of creating a new class of psychopharmaceuticals with rapid action and a favorable safety profile.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Vistagen Therapeutics
Vistagen Therapeutics develops nasal sprays for the rapid relief of anxiety and depression. The company has no tangible assets. Its market capitalization is a bet on its novel approach to treating mental disorders. The chart shows extreme volatility, as the company's valuation depends on clinical trial results, which are difficult to predict.
Market to book capitalization ratio in a market segment - Neuro
Vistagen Therapeutics is developing nasal sprays for the treatment of anxiety disorders. It's a clinical-stage company. Its market capitalization is based almost entirely on the belief in the success of its lead product. The chart shows a huge gap between this hope and the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Vistagen Therapeutics is developing nasal sprays for the rapid treatment of anxiety disorders. The chart shows how the market is pricing this innovative approach to mental health. The company's market capitalization is a pure bet on the success of its clinical trials and the potential of its drugs to change the lives of people suffering from anxiety.
Debts of the company, segment and market as a whole
VTGN - Company debts Vistagen Therapeutics
Vistagen Therapeutics develops innovative treatments for anxiety disorders and depression. For the clinical-stage biopharmaceutical company, debt is a way to finance expensive trials. This chart shows how the company secures resources to address serious mental health issues.
Market segment debts - Neuro
Vistagen Therapeutics develops new drugs for the treatment of anxiety and depressive disorders using innovative mechanisms of action. Mental health is a huge market. The chart shows the financial norms for the pharmaceutical sector, against which Vistagen is raising capital to conduct clinical trials of its unconventional approaches to treating CNS disorders.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Vistagen Therapeutics
Vistagen Therapeutics develops innovative drugs for the treatment of anxiety disorders and depression. Psychiatry is one of the most challenging areas for clinical trials. This chart shows how the company finances its research. A high debt load increases the risks if its drugs fail to prove effective.
Market segment debt to market segment book capitalization - Neuro
Developing sprays for mental disorders like Vistagen's is an innovative approach in neuroscience. This chart shows how the biotech sector as a whole funds its R&D. It helps us understand how Vistagen Therapeutics' financial model, with its unique drug delivery system, differs from companies producing traditional pills and injections.
Debt to book value of all companies in the market
Vistagen Therapeutics develops drugs to treat anxiety disorders and depression. Research in the central nervous system is complex and requires long-term financing. The chart shows how their debt burden compares to the overall risk and debt capacity of the pharmaceutical market.
P/E of the company, segment and market as a whole
P/E - Vistagen Therapeutics
This figure for Vistagen Therapeutics, a company developing drugs to treat anxiety disorders and depression, reflects investor expectations. The company's value is determined not by current profits, but by the potential of its innovative nasal sprays to revolutionize psychiatry. The chart is sensitive to clinical trial results.
P/E of the market segment - Neuro
This indicator represents the average valuation for the biotech sector in which Vistagen Therapeutics operates. It reflects the overall level of hope and expectation in the field of mental health treatments. The chart serves as a barometer of investor confidence in the future of drugs to combat anxiety and depression.
P/E of the market as a whole
Vistagen Therapeutics is developing nasal sprays for the rapid relief of anxiety and the treatment of depression. This is a pioneering approach to psychiatry. The company's success depends entirely on the results of clinical trials and regulatory approval. This chart reflects the biotech sentiment and helps understand how the market perceives the potential of Vistagen's drugs to change the paradigm of mental health treatment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Vistagen Therapeutics
Vistagen Therapeutics is developing new medications for anxiety disorders and depression, including a fast-acting nasal spray. The company's future depends on the success of its drugs in late-stage clinical trials. This timeline reflects investor expectations regarding the potential breakthrough in mental health treatment and the commercial prospects of its innovative products.
%20P%2FE%20Vistagen%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Vistagen-Therapeutics&v=1772662160531 "Chart of the company's future (projected) P/E Vistagen Therapeutics")
Future (projected) P/E of the market segment - Neuro
Vistagen Therapeutics develops medications for anxiety disorders and depression, including innovative nasal sprays that are expected to act very quickly. This is a promising area of psychiatry. The chart reflects expectations for the biotech sector, helping to assess the market's confidence in Vistagen's new approach to treating mental illnesses.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772662160545 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Vistagen Therapeutics is developing new drugs for anxiety and depression, including fast-acting nasal sprays. This chart of overall expectations illustrates investor sentiment toward the biotech. Market optimism facilitates funding to address one of the most pressing issues in mental health, where there is a huge need for new, effective treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772662160559 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Vistagen Therapeutics
Vistagen Therapeutics develops new medications to treat anxiety disorders and depression. This chart reflects the financial costs of addressing complex mental health issues. Future profits are entirely dependent on the success of clinical trials of its nasal sprays and their potential approval as a new class of anxiolytics.
Profit of companies in the market segment - Neuro
Office Properties Income Trust (OPI) is a REIT that owns a portfolio of office buildings, primarily leased to government agencies. This chart shows how focusing on reliable tenants like the government provides stable cash flow, but general trends in the office sector, such as remote work, still pose long-term challenges to profitability.
Overall market profit
Vistagen Therapeutics is developing nasal sprays for the rapid treatment of anxiety disorders. Given the prevalence of these conditions, the potential market for its products is enormous. The company's success depends solely on the results of clinical trials and regulatory approval, which could change the paradigm of mental health treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Vistagen Therapeutics
Vistagen Therapeutics develops innovative medications for anxiety disorders and depression, specifically fast-acting nasal sprays. The company's revenue forecast depends on the success of its clinical trials. This chart shows how analysts assess the potential of its drugs to address the enormous need for new treatments for mental illnesses.
%20profit%20of%20the%20company%20Vistagen%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Vistagen-Therapeutics&v=1772662160606 "Graph of future (projected) profit of the company Vistagen Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Vistagen Therapeutics is developing new medications for anxiety disorders and depression, including fast-acting nasal sprays. The company aims to offer an alternative to traditional antidepressants. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the enormous need for new, more effective treatments for mental disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772662160629 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Vistagen Therapeutics develops drugs to treat anxiety disorders and depression. Demand for such drugs may be countercyclical, but development requires significant investment. This earnings forecast chart is important because it determines investor risk appetite, which determines the funding of biotech companies working on breakthrough drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772662160657 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Vistagen Therapeutics
Vistagen Therapeutics is developing new drugs for the treatment of anxiety disorders and depression, including a fast-acting nasal spray. The company has no commercial revenue. The chart reflects high investor expectations regarding the potential of its drugs to address the enormous need for new, more effective treatments for mental illness.
P/S market segment - Neuro
Vistagen Therapeutics is a clinical-stage biopharmaceutical company developing novel medications for anxiety and depression, including rapid-release nasal sprays. This chart shows the average valuation in the sector, providing insight into the market's perceived revenue potential for Vistagen's innovative approaches to mental health.
P/S of the market as a whole
Vistagen Therapeutics develops new drugs for the treatment of anxiety disorders and depression, including fast-acting nasal sprays. The company aims to address pressing mental health issues. This chart, showing average valuations, clearly demonstrates the gap between the valuations of traditional businesses and biotech companies with breakthrough potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Vistagen Therapeutics
Vistagen Therapeutics is developing new drugs for the treatment of anxiety disorders and depression, including an innovative nasal spray. This chart reflects investor expectations for the future success of its lead candidate. The estimate is based on potential sales revenues based on successful clinical trials and regulatory approval.
%20P%2FS%20Vistagen%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Vistagen-Therapeutics&v=1772662160706 "The graph of the company's future (projected) P/S Vistagen Therapeutics")
Future (projected) P/S of the market segment - Neuro
Vistagen Therapeutics is developing nasal sprays for the rapid relief of anxiety and the treatment of depression. Its drugs are not benzodiazepines and have a novel mechanism of action. The chart shows how investors estimate Vistagen's future sales, reflecting the huge potential market for innovative and safe anxiety treatments.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772662160715 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This graph reflects the hopes for mental health treatments. Vistagen Therapeutics is developing innovative nasal sprays for the rapid relief of anxiety symptoms. The potential of their products to offer patients a fast-acting and safe alternative to existing medications fuels optimism for the future of psychiatry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772662160717 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Vistagen Therapeutics
Vistagen Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments for anxiety disorders and depression. The company currently has no commercial products, and its revenue curve reflects collaboration revenue rather than sales. Future growth will depend on the success of clinical trials.
Sales of companies in the market segment - Neuro
Vistagen Therapeutics develops innovative medications for the treatment of anxiety disorders and depression, including fast-acting nasal sprays. This chart shows total revenue in the neurosciences pharmaceutical segment. It illustrates the enormous need for new, more effective, and faster-acting mental health treatments, where Vistagen offers its approach.
Overall market sales
Vistagen Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of anxiety disorders and depression, including fast-acting nasal sprays. Its future depends on success in clinical trials. This overall economic outlook indirectly impacts the company through the availability of funding for mental health research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Vistagen Therapeutics
Vistagen Therapeutics develops innovative medications for anxiety disorders and depression, including fast-acting nasal sprays. The company's future depends on the success of clinical trials. The chart shows analysts' speculative forecasts, which are betting on a new approach to treating central nervous system disorders.
%20sales%20of%20the%20company%20Vistagen%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Vistagen-Therapeutics&v=1772662160770 "Schedule of future (projected) sales of the company Vistagen Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Vistagen Therapeutics is developing nasal sprays for the rapid relief of anxiety symptoms. The company aims to create non-sedating medications for on-demand anxiety treatment. This chart reflects forecasts for the entire neuroscience pharmaceutical segment, showing analysts' overall expectations for the mental health market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772662160771 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Vistagen Therapeutics is developing new drugs for the treatment of anxiety disorders and depression. The company is in late-stage clinical trials. Its success depends on regulatory approval and commercial launch. This overall economic climate impacts the healthcare system and the ability of patients and insurers to afford new medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772662160772 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Vistagen Therapeutics
Vistagen Therapeutics is developing new medications for the treatment of anxiety and depression. This metric is a financial reflection of its progress in the field of mental health. It demonstrates the level of investment in clinical trials required to bring innovative drugs to market and achieve future commercial success.
Market segment marginality - Neuro
Vistagen Therapeutics is developing nasal sprays for the rapid treatment of anxiety disorders. Profitability will depend on the success of clinical trials and regulatory approval. This metric reflects the company's operational structure in the innovative field of neurology and psychiatry compared to its competitors.
Market marginality as a whole
Vistagen Therapeutics is developing nasal sprays for the rapid treatment of anxiety disorders. Their medications are non-systemic, which may reduce side effects. The company's success depends entirely on the results of clinical trials. This overall profitability curve doesn't affect their business, but it may impact the availability of funding for pharmaceutical development.
Employees in the company, segment and market as a whole
Number of employees in the company Vistagen Therapeutics
Vistagen Therapeutics develops innovative medications for anxiety disorders and depression, including nasal sprays. Being in the clinical stage, its staff is small. This chart shows the dynamics of a small team of scientists and clinical research specialists working to bring a new class of psychopharmaceuticals to market.
Share of the company's employees Vistagen Therapeutics within the market segment - Neuro
Vistagen Therapeutics is developing new pheromone sprays for the treatment of anxiety disorders. This chart shows the concentration of unique neuroscientists and chemists in this innovative field. This proportion reflects its innovative approach to psychiatry, offering non-systemic treatments.
Number of employees in the market segment - Neuro
Vistagen Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of anxiety disorders and depression. This chart shows overall employment in the neuroscience sector. It illustrates the high need for new, more effective, and safer treatments for mental illnesses, which is Vistagen's core mission.
Number of employees in the market as a whole
Vistagen Therapeutics is developing new medications for anxiety disorders and depression, focusing on rapid-onset nasal sprays. Mental health is a pressing issue. This employment chart also reflects the growth of the healthcare sector, where companies working on socially significant problems attract investment and create jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Vistagen Therapeutics (VTGN)
Vistagen Therapeutics is a biopharmaceutical company developing drugs to treat anxiety disorders and depression. This chart is a prime example of biotech. The company's very high market capitalization per employee means the market isn't evaluating current operations, but the potential for breakthrough drugs that could help millions of people. The value lies in the science, not the staff.
%20of%20the%20company%20Vistagen%20Therapeutics%20(VTGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Vistagen-Therapeutics-VTGN&v=1772662160835 "Chart of market capitalization per employee (in thousands of dollars) of the company Vistagen Therapeutics (VTGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Vistagen Therapeutics develops new medications for the treatment of anxiety disorders and depression, an area with a huge unmet need. The company's market cap reflects the company's expectations for the success of its drugs. This metric demonstrates the enormous value the market places on the work of its scientific team, which is focused on solving one of the most pressing mental health issues.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772662160846 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Vistagen Therapeutics is a biopharmaceutical company developing nasal sprays for the treatment of anxiety and depression. Its valuation reflects its success in clinical trials. The high valuation per employee reflects the huge potential market for its products if they prove safe and effective.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772662160853 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Vistagen Therapeutics (VTGN)
Vistagen Therapeutics is a biotech R&D company focused on drugs for anxiety disorders and depression (nasal sprays). This is pure science. This metric demonstrates their capital burn rate—the net loss (expenses for clinical trials) per employee.
%20Chart%20Vistagen%20Therapeutics%20(VTGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Vistagen-Therapeutics-VTGN&v=1772662160869 "Company Profit Per Employee (in thousands of dollars) Chart Vistagen Therapeutics (VTGN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Vistagen Therapeutics is a biotech company developing drugs to treat anxiety disorders and depression. This metric is irrelevant at the clinical stage. The graph shows the norm for the pharmaceutical industry. If successful, their innovative sprays could capture a huge market, generating profit per employee many times higher than the industry benchmark.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772662160874 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Vistagen (VTGN) is a biopharmaceutical company specializing in drugs for anxiety and depression, particularly nasal sprays. It's in neuroscience. This chart shows the economics of their R&D. The company is in the clinical stage, and every scientist employed is an investment in a future blockbuster, meaning negative profit margins.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772662160875 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Vistagen Therapeutics (VTGN)
For Vistagen Therapeutics, a company developing drugs to treat anxiety disorders and depression, this graph reflects the clinical trial stage. Future revenue growth per employee depends entirely on the approval and commercial success of its innovative nasal sprays.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Vistagen-Therapeutics-VTGN&v=1772662160885 "Sales chart per company employee Vistagen Therapeutics (VTGN)")
Sales per employee in the market segment - Neuro
Vistagen Therapeutics is a biopharmaceutical company developing medications for anxiety disorders and depression, specifically nasal sprays. This is R&D in neuroscience. This metric reflects the average revenue per employee in the segment. It allows one to assess how productive their R&D team is compared to other biotech companies in the mental health field.
Sales per employee for the market as a whole
Vistagen (VTGN) is a clinical-stage biopharmaceutical company developing new drugs for the treatment of anxiety disorders and depression. Currently, its staff consists entirely of researchers. This metric is critical for VTGN: it's at zero. Future growth will signal the success of their R&D platform and the receipt of partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company Vistagen Therapeutics (VTGN)
Vistagen Therapeutics is developing nasal sprays for anxiety disorders, an unconventional approach. The company has suffered several significant failures in clinical trials. This chart shows how many investors are betting that its current programs will suffer the same fate and that its drugs will never prove effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Vistagen-Therapeutics-VTGN&v=1772662160967 "Short Shares Chart for the Company Vistagen Therapeutics (VTGN)")
Shares shorted by market segment - Neuro
Vistagen (VTGN) is a biopharmaceutical company developing fast-acting medications (including a nasal spray) for the treatment of anxiety and depression. This chart shows a general short position in the psychiatric pharmacology sector. It reflects the high skepticism surrounding their novel mechanisms of action and a notorious history of failure in CNS drug development.
Shares shorted by the overall market
Vistagen (VTGN) is a clinical-stage biotech company working on depression. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They dump unprofitable companies en masse.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Vistagen Therapeutics (VTGN)
Vistagen (VTGN) is a biotech betting on a nasal spray for anxiety (fasedienol). It's a binary bet on whether the FDA will approve it or not. This chart measures the extremes of these expectations. It shows when the stock is overbought on hopes for Phase 3 data or oversold after another dip.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Vistagen-Therapeutics-VTGN&v=1772662161023 "RSI 14 indicator chart for the company's stock Vistagen Therapeutics (VTGN)")
RSI 14 Market Segment - Neuro
Vistagen (VTGN) is a "biotech" *anxiety* "killer." They're developing *nasal sprays* (fasedienol) for *quick* relief of *social anxiety*. The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is VTGN's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Vistagen Therapeutics (VTGN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VTGN (Vistagen Therapeutics)
Vistagen Therapeutics is a biopharmaceutical company developing next-generation medications (pheromones, nasal sprays) for the treatment of anxiety disorders such as social phobia. This chart shows the speculative average price target from analysts based on their belief in this unconventional R&D approach.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VTGN-Vistagen-Therapeutics&v=1772662161080 "A chart showing analyst consensus forecasts for the expected stock price. VTGN (Vistagen Therapeutics)")
The difference between the consensus estimate and the actual stock price VTGN (Vistagen Therapeutics)
VTGN - Vistagen is a biotech company developing a revolutionary new class of drugs: nasal sprays for immediate anxiety relief (social anxiety disorder). This chart shows the difference between the current price and the analyst consensus forecast. It reflects their belief in the vast but complex anxiety treatment market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VTGN-Vistagen-Therapeutics&v=1772662161109 "A chart showing the difference between the consensus forecast and the actual stock price. VTGN (Vistagen Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Vistagen (VTGN) is a biotech company developing nasal sprays (pheromones) for the rapid relief of anxiety and depression. It's not an antidepressant, but an "emergency" treatment. This chart shows general expectations for the neuroscience sector. It reflects whether experts believe in this innovative approach to anxiety treatment.
Analysts' consensus forecast for the overall market share price
Vistagen Therapeutics is a biotech company developing drugs for anxiety and depression, particularly nasal sprays. This chart shows overall risk appetite. For Vistagen, which operates in the complex field of psychiatry, overall market optimism is critical to attracting the capital needed to fund long-term trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Vistagen Therapeutics
Vistagen (VTGN) is a clinical-stage biotech focused on the central nervous system. Their specialty is nasal sprays (not pills) for immediate relief of anxiety (social anxiety disorder) and depression. This chart represents their R&D bet. Its valuation represents the market's binary belief that their (very risky) Phase 3 clinical trials will be successful.
AKIMA Market Segment Index - Neuro
Vistagen Therapeutics is a biotech company specializing in anxiety disorders, specifically pheromone nasal sprays. This chart shows the average index for the neurosegment. It provides investors with a benchmark for how Vistagen's innovative approach to treating the central nervous system compares to the average.
The AKIM Index for the overall market
Vistagen Therapeutics is a biotech company developing nasal sprays (ferins) for the rapid treatment of anxiety and depression. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative, clinically driven psychiatric story compares to overall economic trends.
